47 patents
Page 3 of 3
Utility
Ketogenic Diet Compatible Fenfluramine Formulation
19 Aug 20
A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient.
Khawla ABU-IZZA, David HICKMAN, Glenn MORRISON, Brooks M. BOYD
Filed: 3 May 20
Utility
Methods of Treating Lennox-gastaut Syndrome Using Fenfluramine
12 Aug 20
A method of treating and/or preventing symptoms of Lennox-Gastaut Syndrome (LGS) also known as Lennox Syndrome in a patient such as a patient previously diagnosed with Lennox Syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient.
Stephen J. FARR, Bradley S. GALER
Filed: 30 Apr 20
Utility
Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same
5 Aug 20
Drug combinations and their use are disclosed.
Stephen J. FARR, BROOKS BOYD
Filed: 5 Mar 20
Utility
Metabolism resistant fenfluramine analogs and methods of using the same
22 Jun 20
Metabolism-resistant fenfluramine analogs are provided.
Stephan J. Farr, Brooks M. Boyd
Filed: 19 Dec 16
Utility
Ketogenic diet compatible fenfluramine formulation
15 Jun 20
A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient.
Khawla Abu-Izza, David Hickman, Glenn Morrison, Brooks M. Boyd
Filed: 23 Sep 18
Utility
Methods of Treating Doose Syndrome Using Fenfluramine
3 Jun 20
A method of treating and/or preventing symptoms of Doose syndrome in a patient such as a patient previously diagnosed with Doose syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient.
Brooks BOYD, Stephen J. FARR, Bradley GALER
Filed: 3 May 18
Utility
Formulation for inhibiting formation of 5-HT
30 Mar 20
Drug combinations and their use are disclosed.
Stephen J. Farr, Brooks Boyd
Filed: 15 Nov 18